Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 3 · below the Ichimoku cloud · RSI 30 (oversold) · MACD above its signal · 2% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $576.8K | 0.00% | 1.04M | +469% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CNTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2025 | Lehr Martin AChief Executive Officer | Purchase at price 0.70 per share. | 100K | $70.08K |
| Jun 5, 2025 | Minai-Azary Jennifer LynnChief Financial Officer | Purchase at price 0.64 per share. | 40K | $25.49K |
| Jun 5, 2025 | Levit Alex C.Officer | Purchase at price 0.58 per share. | 20K | $11.52K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 77.6 | -13.8 | 16.4 | -9.9 | 20.8 | -80.6 | 8.1 | -34.9 | -23.1 | -8.3 | −81.3% | ||
| 2025 | -13.0 | -2.7 | -31.1 | 41.7 | -33.4 | 13.5 | 11.5 | 15.1 | 15.4 | 12.5 | 2.8 | 31.3 | +40.0% |
| 2024 | -9.7 | 11.8 | 21.1 | -2.6 | 47.3 | 1.3 | 7.7 | 13.9 | -20.3 | 11.2 | -30.3 | -30.9 | −7.1% |
| 2023 | 62.6 | -27.4 | -27.0 | 3.4 | 49.7 | 83.9 | -31.2 | -6.4 | 46.6 | -29.8 | -19.8 | 32.9 | +73.3% |
| 2022 | -23.3 | -7.8 | 15.4 | -33.2 | 54.5 | -5.4 | -10.8 | 0.5 | -41.6 | 13.5 | 9.5 | -52.8 | −75.5% |
| 2021 | 19.4 | -61.3 | −53.8% |
Buy / hold / sell counts
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.